Search and Browse
Download
Enter Data
| Target/Host (Institution) | Ligand | Target/Host Links | Ligand Links | Trg + Lig Links | Ki nM | ΔG° kJ/mole | IC50 nM | Kd nM | EC50/IC50 nM | koff s-1 | kon M-1s-1 | pH | Temp °C |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141416 (US10668051, Compound Example 67 | US8921364, 67) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet  | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 20.4 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141426 (US10668051, Compound Example 84 | US8921364, 84) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 20.8 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141438 (US10668051, Compound Example 104 | US8921364, 104) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 23.0 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141428 (US10668051, Compound Example 87 | US8921364, 87) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 32.6 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141421 (US10668051, Compound Example 78 | US8921364, 78) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 34.1 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141424 (US10668051, Compound Example 82 | US8921364, 82) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 35.7 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141396 (US10668051, Compound Example 7 | US8921364, 7) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 36.4 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141444 (US10668051, Compound Example 114 | US8921364, 114) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 37.6 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141442 (US10668051, Compound Example 111 | US8921364, 111) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 47.2 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141419 (US10668051, Compound Example 74 | US8921364, 74) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 48.0 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141425 (US10668051, Compound Example 83 | US8921364, 83) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 48.2 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141418 (US10668051, Compound Example 72 | US8921364, 72) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 48.2 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141441 (US10668051, Compound Example 108 | US8921364, 108) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 50.6 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141448 (US10668051, Compound Example 126 | US8921364, 126) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 52.6 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141439 (US10668051, Compound Example 106 | US8921364, 106) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 60 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141402 (US10668051, Compound Example 28 | US8921364, 28) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 60.3 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141393 (US10668051, Compound Example 1 | US8921364, 1) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 62.4 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141443 (US10668051, Compound Example 113 | US8921364, 113) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 62.6 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141412 (US10668051, Compound Example 56 | US8921364, 56) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 63.2 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141409 (US10668051, Compound Example 49 | US8921364, 49) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 65.5 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141440 (US10668051, Compound Example 107 | US8921364, 107) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 70.3 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141411 (US10668051, Compound Example 53 | US8921364, 53) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 72.0 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141445 (US10668051, Compound Example 122 | US8921364, 122) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 72.1 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141434 (US10668051, Compound Example 93 | US8921364, 93) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 81.3 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141429 (US10668051, Compound Example 88 | US8921364, 88) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 98.6 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141436 (US10668051, Compound Example 100 | US8921364, 100) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 99.7 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141414 (US10668051, Compound Example 60 | US8921364, 60) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 120 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141422 (US10668051, Compound Example 79 | US8921364, 79) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 124 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141413 (US10668051, Compound Example 57 | US8921364, 57) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 125 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141399 (US10668051, Compound Example 17 | US8921364, 17) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 130 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141397 (US10668051, Compound Example 15 | US8921364, 15) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 141 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141403 (US10668051, Compound Example 33 | US8921364, 33) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 145 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141427 (US10668051, Compound Example 86 | US8921364, 86) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 147 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141437 (US10668051, Compound Example 101 | US8921364, 101) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 150 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141432 (US10668051, Compound Example 91 | US8921364, 91) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 159 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141433 (US10668051, Compound Example 92 | US8921364, 92) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 159 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141406 (US10668051, Compound Example 37 | US8921364, 37) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 181 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141410 (US10668051, Compound Example 52 | US8921364, 52) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 184 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141404 (US10668051, Compound Example 35 | US8921364, 35) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 185 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141423 (US10668051, Compound Example 80 | US8921364, 80) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 194 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141430 (US10668051, Compound Example 89 | US8921364, 89) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 206 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141394 (US10668051, Compound Example 2 | US8921364, 2) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 207 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141405 (US10668051, Compound Example 36 | US8921364, 36) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 224 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141431 (US10668051, Compound Example 90 | US8921364, 90) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 232 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141398 (US10668051, Compound Example 16 | US8921364, 16) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 244 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141415 (US10668051, Compound Example 66 | US8921364, 66) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 255 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141395 (US10668051, Compound Example 4 | US8921364, 4) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 256 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141420 (US10668051, Compound Example 76 | US8921364, 76) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 269 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141446 (US10668051, Compound Example 124 | US8921364, 124) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 295 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141447 (US10668051, Compound Example 125 | US8921364, 125) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 373 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141408 (US8921364, 45) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 436 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141400 (US10668051, Compound Example 19 | US8921364, 19) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 457 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141435 (US10668051, Compound Example 97 | US8921364, 97) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem | US Patent | n/a | n/a | 600 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141417 (US10668051, Compound Example 71 | US8921364, 71) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 604 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141407 (BDBM444852 | US8921364, 39) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 851 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
| EF-hand calcium-binding domain-containing protein 4B (Homo sapiens (Human)) | BDBM141401 (US10668051, Compound Example 22 | US8921364, 22) | PDB KEGG UniProtKB/SwissProt GoogleScholar AffyNet | PC cid PC sid UniChem Similars | US Patent | n/a | n/a | 968 | n/a | n/a | n/a | n/a | n/a | 37 |
Rhizen Pharmaceuticals SA US Patent | Assay Description Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat # T9033) induced endoplasmic calcium release in Jurkat cells. (see Yasu... | US Patent US8921364 (2014) BindingDB Entry DOI: 10.7270/Q2N58K3N | |||||||||||
| More data for this Ligand-Target Pair | |||||||||||||
